[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-unresectable-hepatocellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-unresectable-hepatocellular-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100629717","phase-1-a-study-of-shr-2524-plus-bevacizumab-in-the-first-line-treatment-of-advanced-hepatocellular-carcinoma-100629717",false,"NCT07478302","A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma","To Investigate the Pharmacokinetics, Safety, Tolerability and Efficacy of SHR-2524 Combined With Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) in an Open-label, Multicenter Phase I Clinical Trial","Inclusion Criteria:\n\n1. ≥ 18 years old;\n2. Advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or clinical diagnosis;\n3. The Barcelona clinical liver cancer stage was B or C;\n4. Has not previously received systemic antitumor therapy for HCC;\n5. At least one measurable lesion according to RECIST v1.1 criteria;\n6. Child-Pugh score of A or B7 ;\n7. ECOG score 0 -1;\n8. The expected survival time was ≥12 weeks;\n9. The major organs functioned well;\n10. Has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Hepatobiliary cell carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, and fibrolamellar hepatocellular carcinoma confirmed by histology or cytology;\n2. Patients with active malignant tumors other than HCC within 5 years or at the same time; Localized tumors that had been cured, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, and breast cancer in situ, could be enrolled;\n3. Previous allogeneic organ transplantation (e.g., liver transplantation);\n4. The current liver tumor burden is greater than 50% of the total liver volume;\n5. CTCAE grade 3 bleeding had occurred within 6 months or CTCAE grade 2 nongastrointestinal bleeding had occurred within 3 months before the first dose;\n6. Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before the first dose;\n7. Major vascular disease had occurred within 6 months before the first dose;\n8. Current concomitant interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy;\n9. Innate or acquired immune deficiency (such as HIV infection);\n10. Severe infection occurred within 28 days before the first dose.","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.",[26],"Advanced Unresectable Hepatocellular Carcinoma","RECRUITING","2026-04-29",{"date":30,"type":31},"2026-05-01","ACTUAL",{"date":33,"type":31},"2026-04-14",{"date":35,"type":20},"2027-12",{"name":37,"class":38},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100606429","phase-2-evaluation-of-rbs2418-in-combination-with-tremelimumab-plus-durvalumab-in-participants-with-advanced-unresectable-hepatocellular-carcinoma-100606429","NCT07175441","Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. At least 18 years of age on the day of signing informed consent.\n2. Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as first line therapy.\n3. Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available).\n\nExclusion Criteria:\n\n1. BCLC stage D disease at the time of screening or prior to first dose of RBS2418.\n2. Child-Pugh class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment.\n3. Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation).\n4. Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.",{"count":47,"type":20},220,[49],"PHASE2","RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase\u002Fphosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.",[26],[53],"Advanced Unresectable Hepatocellular Carcinoma (HCC)","2026-04-22",{"date":56,"type":31},"2026-04-24",{"date":58,"type":31},"2026-04-10",{"date":60,"type":20},"2027-08",{"name":62,"class":38},"Riboscience, LLC.",4]